CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS

Condition(s) studied

Study summary

Lung cancer remains a significant challenge in oncology, with poor prognosis for patients, especially those with advanced-stage disease. The phenomenon of tumor spread through air spaces (STAS) in pulmonary cancer has garnered attention for its association with aggressive tumor behavior and adverse clinical outcomes. Spread through air spaces identification has been highly debatable on scientific community as an important prognostic feature for distant and locoregional recurrence and as a key player in the differential diagnosis and selection of the appropriate treatment. The aim of this study is to unravel the complexities of STAS-positive lung adenocarcinoma (LUAD) diagnosis and treatment options. For that, we intend to (1) isolate primary lung cancer tissues from early-stages lung adenocarcinoma to fabricate organoid in vitro models and (2) evaluate the microRNA (miRNA) profile of tumor and healthy tissue samples. This is a Hybrid (prospective and retrospective) observational clinical study with a nested translational study.

Eligibility

Primary outcome measure(s)

• Identification and quantification of specific gene miRNAs overexpression's — 1 year
  \- Identify and quantify specific gene miRNAs ubiquitously overexpressed in paraffined tumor tissue and in blood samples of STAS-positive patients in comparison with other LUAD patient group.

Trial sites (2)

More Universidade Nova de Lisboa trials in Portugal